Research programme: monoamine reuptake inhibitors/mu opioid receptor agonists - Merck

Drug Profile

Research programme: monoamine reuptake inhibitors/mu opioid receptor agonists - Merck

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Adolor Corporation
  • Class
  • Mechanism of Action Biogenic monoamine uptake inhibitors; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 16 Dec 2011 Discontinued for Pain in USA (PO)
  • 12 Dec 2011 Adolor Corporation has been acquired and merged into Cubist Pharmaceuticals
  • 20 Aug 2009 Early research in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top